Lista de obras -

A Blueprint to Advance Colorectal Cancer Immunotherapies

artículo científico publicado en 2017

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.

artículo científico publicado en 2016

A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.

artículo científico publicado en 2018

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

artículo científico publicado en 2010

ALDH+ tumor‐initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ‐secretase inhibitor and irinotecan in colorectal cancer ⬇️

artículo científico publicado el 28 de marzo de 2012

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial ⬇️

artículo científico publicado el 16 de julio de 2012

An in vivo platform for translational drug development in pancreatic cancer

scientific article published on 01 August 2006

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.

artículo científico publicado en 2015

Assessment of celecoxib pharmacodynamics in pancreatic cancer

artículo científico publicado en 2006

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.

artículo científico publicado en 2013

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

artículo científico publicado en 2015

Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment

artículo científico publicado en 2020

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer

artículo científico publicado en 2014

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

artículo científico publicado en 2010

Impact of neoadjuvant chemoradiation on perioperative outcomes in patients with rectal cancer.

artículo científico publicado en 2017

Novel agents in the treatment of metastatic colorectal cancer

artículo científico publicado en 2010

Patient-derived tumour xenografts as models for oncology drug development

artículo científico publicado en 2012

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors ⬇️

artículo científico publicado el 23 de abril de 2012

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies

artículo científico publicado en 2014

Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers

artículo científico publicado en 2015

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

artículo científico publicado en 2017

Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial ⬇️

artículo científico publicado el 16 de julio de 2012

Targeting the WNT Signaling Pathway in Cancer Therapeutics

artículo científico

Therapeutic Approaches to RAS Mutation

artículo científico publicado en 2016

Lista de obras de

A Blueprint to Advance Colorectal Cancer Immunotherapies

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.

A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

ALDH+ tumor‐initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ‐secretase inhibitor and irinotecan in colorectal cancer ⬇️

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial ⬇️

An in vivo platform for translational drug development in pancreatic cancer

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.

Assessment of celecoxib pharmacodynamics in pancreatic cancer

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

Impact of neoadjuvant chemoradiation on perioperative outcomes in patients with rectal cancer.

Novel agents in the treatment of metastatic colorectal cancer

Patient-derived tumour xenografts as models for oncology drug development

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors ⬇️

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies

Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial ⬇️

Targeting the WNT Signaling Pathway in Cancer Therapeutics

Therapeutic Approaches to RAS Mutation